David A. Siegel Eagle Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 185,058 shares of EGRX stock, worth $175,805. This represents 0.0% of its overall portfolio holdings.

Number of Shares

185,058

Previous 224,817 17.69%

Holding current value

$175,805

Previous $1.26 Million 45.47%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.71 - $6.07 $147,505 - $241,337	-39,759 Reduced 17.69%	185,058 $686,000
Q2 2024 Aug 14, 2024	SELL	$3.34 - $5.6 $38,410 - $64,399	-11,500 Reduced 4.87%	224,817 $1.26 Million
Q1 2024 May 15, 2024	BUY	$4.26 - $6.51 $60,918 - $93,093	14,300 Added 6.44%	236,317 $1.24 Million
Q4 2023 Feb 14, 2024	BUY	$4.63 - $15.21 $923,685 - $3.03 Million	199,500 Added 886.0%	222,017 $1.16 Million
Q3 2023 Nov 14, 2023	BUY	$15.21 - $22.88 $342,483 - $515,188	22,517 New	22,517 $355,000
Q4 2021 Feb 14, 2022	SELL	$45.82 - $56.9 $197,026 - $244,670	-4,300 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$43.79 - $55.78 $998,412 - $1.27 Million	-22,800 Reduced 84.13%	4,300 $240,000
Q2 2021 Aug 16, 2021	SELL	$36.86 - $44.5 $3.12 Million - $3.76 Million	-84,600 Reduced 75.74%	27,100 $1.16 Million
Q1 2021 May 17, 2021	BUY	$40.32 - $50.97 $1.2 Million - $1.51 Million	29,700 Added 36.22%	111,700 $4.66 Million
Q4 2020 Feb 16, 2021	BUY	$41.72 - $51.34 $2.79 Million - $3.43 Million	66,900 Added 443.05%	82,000 $3.82 Million
Q3 2020 Nov 16, 2020	BUY	$37.02 - $51.28 $129,570 - $179,480	3,500 Added 30.17%	15,100 $641,000
Q2 2020 Aug 14, 2020	BUY	$43.24 - $55.02 $501,584 - $638,232	11,600 New	11,600 $557,000
Q3 2019 Nov 14, 2019	SELL	$53.25 - $59.98 $564,450 - $635,788	-10,600 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$46.61 - $58.45 $195,762 - $245,490	4,200 Added 65.63%	10,600 $590,000
Q1 2019 May 15, 2019	BUY	$38.66 - $51.82 $247,423 - $331,648	6,400 New	6,400 $323,000
Q3 2018 Nov 14, 2018	SELL	$66.65 - $83.86 $399,900 - $503,160	-6,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$51.25 - $76.62 $307,500 - $459,720	6,000 New	6,000 $454,000
Q4 2017 Feb 14, 2018	SELL	$49.6 - $60.87 $238,080 - $292,176	-4,800 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$46.62 - $60.36 $223,776 - $289,728	4,800	4,800 $286,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.59M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $12.4M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account